Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study
暂无分享,去创建一个
R. Landewé | E. Matteson | J. Smolen | J. Kay | N. Gaylis | J. Wollenhaupt | E. Hsia | M. Doyle | Stephen Xu | F. Murphy | Yiying Zhou